Search results
Showing 16 to 30 of 41 results for semaglutide
Our forward view highlights the areas we will prioritise in the coming year.
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]
In development Reference number: GID-TA11414 Expected publication date: 10 June 2026
See a complete list of indicators currently in consultation. Our indicators measure outcomes that reflect the quality of care or processes.
View a complete list of indicators currently being developed. Our indicators measure outcomes that reflect the quality of care or processes.
Semaglutide for managing overweight and obesity in children 6 to 11 years [TSID12381]
Awaiting development Reference number: GID-TA12020 Expected publication date: TBC
See a complete list of all our guidance and quality standards currently open for consultation
Awaiting development Reference number: GID-TA11847 Expected publication date: TBC
Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services.
Injection for more than a million people to help prevent heart attacks and strokes recommended
People who have had a heart attack, stroke, or serious circulation problem in their legs, and who also carry excess weight, can now be offered a weekly injection to help protect them from a further life-threatening event, NICE has said.
This quality standard covers prevention, behavioural management, assessment, and treatment of overweight, obesity and central adiposity in children and young people aged over 2 years, and adults. This includes those with established comorbidities, and those with risk factors for other medical conditions. It describes high-quality care in priority areas for improvement.
View quality statements for QS212Show all sections
Sections for QS212
- Quality statements
- Quality statement 1: Recording BMI and waist-to-height ratio in adults
- Quality statement 2: Recording BMI in children and young people aged over 2 years
- Quality statement 3: Access to services for people with a learning disability
- Quality statement 4: Maintaining details of local and national overweight and obesity management interventions and services
- Quality statement 5: Providing information about local and national weight management interventions and services
- Quality statement 6: Wraparound care alongside medicines for weight management
- Quality statement 7: Advice and support after stopping medicines for weight management or completing behavioural interventions
This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on overweight and obesity. It does not cover pregnancy.
Show all sections
Sections for NG246
Oral semaglutide for managing overweight and obesity [ID6188]
Discontinued Reference number: GID-TA11149
In development Reference number: GID-TA11104 Expected publication date: TBC
Major changes to type 2 diabetes treatment could save thousands of lives
New guidance means millions of people will get access to medicines that protect the heart and kidneys, while NHS savings of £560 million from using generic dapagliflozin can be reinvested elsewhere in NHS care.